Companies › Anavex Life Sciences
1 active drug program in 1 registered trial: 1 Phase 2; Psychiatry.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ANAVEX3-71 Dual SIGMAR1 receptor agonist and M1 positive allosteric modulator | SIGMAR1, CHRM1 | Phase 2 | Schizophrenia | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06245213 | ANAVEX3-71 | Phase 2 | Schizophrenia | Psychiatry | Jun 2025 |
Cash of $118m on 2026-06-30; operating cash outflow about $28m a year; runway about 51 months at that burn, to Oct 2030
Press releases filed as 8-K in the last year:
Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Seaport Therapeutics Definium Therapeutics US NeuroRx Bazelet Nehushtan Autobahn Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.